The SLE clinical trial analysis report delivers important insights into ongoing research of 140+ pipeline SLE drugs, clinical strategies, upcoming therapeutics, and commercial analysis.

Systemic Lupus Erythematosus (SLE) is a chronic autoimmune disorder in which the body’s immune system mistakenly attacks its own healthy tissues. This condition can affect multiple organs, including ...

Systemic Lupus Erythematosus (SLE) is a chronic autoimmune disease characterised by the production of autoantibodies and the formation of immune complexes, leading to inflammation and multi-organ ...

Anifrolumab treatment is linked to improved disease activity and reduced steroid use and has an acceptable safety profile in routine care of patients with systemic lupus erythematosus.

Objectives Fatigue is one of the most common and debilitating symptoms experienced by patients with systemic lupus erythematosus (SLE). Previous studies revealed the association of fatigue with ...

Biogen announced positive results from the Phase 2 part of the AMETHYST Phase 2/3 study (part A) of investigational therapy, ...

A pivotal trial of obinutuzumab has demonstrated the strongest evidence yet of the efficacy of B-cell depletion in systemic ...

Type I interferons are a family of cytokines that play a critical role in the immune system, particularly in antiviral defence and immunomodulation. In systemic lupus erythematosus (SLE), an ...

Investigators studied GLP-1 receptor agonist use and renal and inflammatory outcomes among patients with systemic lupus erythematosus and type 2 diabetes mellitus.

Saphnelo, a human monoclonal antibody, is a type 1 interferon (INF) receptor antagonist that inhibits a key protein in the immune system called the IFNAR receptor. This protein acts like a transmitter ...